Which has preferable earnings & valuation, GRFS or EXEL?

Exelixis has lower revenue, but higher earnings than Grifols. Exelixis is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.57 $454.82M $0.19 37.74 Exelixis $2.32B 6.36 $782.57M $3.18 18.71

Is GRFS or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Grifols' net margin of 5.54%. Exelixis' return on equity of 42.17% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Exelixis 35.33% 42.17% 31.76%

Does the media prefer GRFS or EXEL?

In the previous week, Exelixis had 18 more articles in the media than Grifols. MarketBeat recorded 24 mentions for Exelixis and 6 mentions for Grifols. Exelixis' average media sentiment score of 0.34 beat Grifols' score of 0.05 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Exelixis 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ASND or GRFS?

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 17.09 -$258M $12.89 17.32 Grifols $8.51B 0.57 $454.82M $0.19 37.74

Does the media prefer ASND or GRFS?

In the previous week, Grifols had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for Grifols and 3 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.56 beat Grifols' score of 0.05 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GRFS or SMMT more profitable?

Grifols has a net margin of 5.54% compared to Summit Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Summit Therapeutics N/A -168.94% -141.92%

Does the media refer more to GRFS or SMMT?

In the previous week, Summit Therapeutics had 1 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Grifols. Summit Therapeutics' average media sentiment score of 0.63 beat Grifols' score of 0.05 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, BBIO or GRFS?

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 24.65 -$724.93M -$3.57 N/A Grifols $8.51B 0.57 $454.82M $0.19 37.74

Does the media refer more to BBIO or GRFS?

In the previous week, BridgeBio Pharma had 4 more articles in the media than Grifols. MarketBeat recorded 10 mentions for BridgeBio Pharma and 6 mentions for Grifols. BridgeBio Pharma's average media sentiment score of 0.45 beat Grifols' score of 0.05 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Grifols 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GRFS or HALO?

In the previous week, Halozyme Therapeutics had 18 more articles in the media than Grifols. MarketBeat recorded 24 mentions for Halozyme Therapeutics and 6 mentions for Grifols. Halozyme Therapeutics' average media sentiment score of 0.80 beat Grifols' score of 0.05 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Halozyme Therapeutics 10 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Grifols (GRFS) Competitors

$7.17 -0.20 (-2.71%)

Closing price 04:00 PM Eastern

Extended Trading

$7.18 +0.01 (+0.14%)

As of 06:56 PM Eastern

Compare

GRFS vs. EXEL, ASND, SMMT, BBIO, and HALO

Should you buy Grifols stock or one of its competitors? Grifols's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Grifols compare to Exelixis?

Grifols (NASDAQ:GRFS) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Grifols currently has a consensus price target of $10.00, suggesting a potential upside of 39.47%. Exelixis has a consensus price target of $50.79, suggesting a potential downside of 14.66%. Given Grifols' higher probable upside, equities research analysts clearly believe Grifols is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

In the previous week, Exelixis had 18 more articles in the media than Grifols. MarketBeat recorded 24 mentions for Exelixis and 6 mentions for Grifols. Exelixis' average media sentiment score of 0.34 beat Grifols' score of 0.05 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Exelixis has a net margin of 35.33% compared to Grifols' net margin of 5.54%. Exelixis' return on equity of 42.17% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Exelixis	35.33%	42.17%	31.76%

Exelixis has lower revenue, but higher earnings than Grifols. Exelixis is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.57	$454.82M	$0.19	37.74
Exelixis	$2.32B	6.36	$782.57M	$3.18	18.71

Grifols has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Exelixis beats Grifols on 13 of the 17 factors compared between the two stocks.

How does Grifols compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Ascendis Pharma A/S has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Grifols has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

In the previous week, Grifols had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for Grifols and 3 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.56 beat Grifols' score of 0.05 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.09	-$258M	$12.89	17.32
Grifols	$8.51B	0.57	$454.82M	$0.19	37.74

Ascendis Pharma A/S has a net margin of 70.99% compared to Grifols' net margin of 5.54%. Ascendis Pharma A/S's return on equity of 32.54% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Grifols	5.54%	6.21%	2.39%

Ascendis Pharma A/S currently has a consensus price target of $313.21, indicating a potential upside of 40.32%. Grifols has a consensus price target of $10.00, indicating a potential upside of 39.47%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Ascendis Pharma A/S beats Grifols on 10 of the 15 factors compared between the two stocks.

How does Grifols compare to Summit Therapeutics?

Grifols (NASDAQ:GRFS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Grifols has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, suggesting that its share price is 251% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to Summit Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Summit Therapeutics	N/A	-168.94%	-141.92%

Grifols has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.57	$454.82M	$0.19	37.74
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

4.6% of Summit Therapeutics shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Grifols currently has a consensus target price of $10.00, indicating a potential upside of 39.47%. Summit Therapeutics has a consensus target price of $28.61, indicating a potential upside of 84.33%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

In the previous week, Summit Therapeutics had 1 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Grifols. Summit Therapeutics' average media sentiment score of 0.63 beat Grifols' score of 0.05 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Summit Therapeutics beats Grifols on 8 of the 15 factors compared between the two stocks.

How does Grifols compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, BridgeBio Pharma had 4 more articles in the media than Grifols. MarketBeat recorded 10 mentions for BridgeBio Pharma and 6 mentions for Grifols. BridgeBio Pharma's average media sentiment score of 0.45 beat Grifols' score of 0.05 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BridgeBio Pharma presently has a consensus price target of $105.42, suggesting a potential upside of 66.54%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 39.47%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Grifols has a net margin of 5.54% compared to BridgeBio Pharma's net margin of -97.03%. Grifols' return on equity of 6.21% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Grifols	5.54%	6.21%	2.39%

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	24.65	-$724.93M	-$3.57	N/A
Grifols	$8.51B	0.57	$454.82M	$0.19	37.74

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Grifols has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

BridgeBio Pharma beats Grifols on 9 of the 15 factors compared between the two stocks.

How does Grifols compare to Halozyme Therapeutics?

Grifols (NASDAQ:GRFS) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Grifols has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.57	$454.82M	$0.19	37.74
Halozyme Therapeutics	$1.40B	8.91	$316.89M	$3.35	32.72

Grifols presently has a consensus target price of $10.00, suggesting a potential upside of 39.47%. Halozyme Therapeutics has a consensus target price of $96.50, suggesting a potential downside of 11.97%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Halozyme Therapeutics had 18 more articles in the media than Grifols. MarketBeat recorded 24 mentions for Halozyme Therapeutics and 6 mentions for Grifols. Halozyme Therapeutics' average media sentiment score of 0.80 beat Grifols' score of 0.05 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	10 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to Grifols' net margin of 5.54%. Halozyme Therapeutics' return on equity of 260.98% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Summary

Halozyme Therapeutics beats Grifols on 12 of the 16 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRFS vs. The Competition

Export

Metric	Grifols	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.02B	$3.93B	$7.27B	$13.21B
Dividend Yield	1.16%	3.65%	2.52%	22.89%
P/E Ratio	37.74	9.71	193.11	18.97
Price / Sales	0.57	1,149.10	561.77	81.05
Price / Cash	5.20	118.50	77.16	53.04
Price / Book	0.57	16.95	10.71	6.03
Net Income	$454.82M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-4.65%	-4.83%	-3.18%	-3.04%
1 Month Performance	-5.03%	-12.20%	-6.61%	-5.16%
1 Year Performance	-24.13%	8.87%	3.69%	-2.48%

Grifols Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRFS Grifols	4.4458 of 5 stars	$7.17 -2.7%	$10.00 +39.5%	-20.9%	$5.02B	$8.51B	37.74	25,247	Analyst Downgrade Short Interest Increase
EXEL Exelixis	2.3523 of 5 stars	$58.36 -0.8%	$50.29 -13.8%	+56.8%	$14.43B	$2.44B	18.31	1,077	Analyst Revision
ASND Ascendis Pharma A/S	4.7985 of 5 stars	$226.87 -0.5%	$310.75 +37.0%	+8.3%	$14.27B	$814.57M	17.74	1,189	Analyst Upgrade
SMMT Summit Therapeutics	2.4558 of 5 stars	$17.45 +1.0%	$28.61 +64.0%	-19.8%	$13.83B	N/A	N/A	265	Upcoming Earnings Options Volume
BBIO BridgeBio Pharma	3.7426 of 5 stars	$67.40 +1.9%	$102.61 +52.3%	+18.5%	$13.08B	$713.07M	N/A	839	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRFS) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grifols (GRFS) Competitors

GRFS vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Grifols compare to Exelixis?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Summary

How does Grifols compare to Summit Therapeutics?

Summary

How does Grifols compare to BridgeBio Pharma?

Summary

How does Grifols compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grifols (GRFS) Competitors

GRFS vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Grifols compare to Exelixis?

Do analysts recommend GRFS or EXEL?

Does the media prefer GRFS or EXEL?

Is GRFS or EXEL more profitable?

Which has preferable earnings & valuation, GRFS or EXEL?

Which has more volatility & risk, GRFS or EXEL?

Do insiders and institutionals hold more shares of GRFS or EXEL?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Which has more volatility & risk, ASND or GRFS?

Does the media prefer ASND or GRFS?

Which has higher earnings and valuation, ASND or GRFS?

Is ASND or GRFS more profitable?

Do analysts prefer ASND or GRFS?

Summary

How does Grifols compare to Summit Therapeutics?

Which has more volatility & risk, GRFS or SMMT?

Is GRFS or SMMT more profitable?

Which has stronger valuation & earnings, GRFS or SMMT?

Do institutionals and insiders believe in GRFS or SMMT?

Do analysts rate GRFS or SMMT?

Does the media refer more to GRFS or SMMT?

Summary

How does Grifols compare to BridgeBio Pharma?

Does the media refer more to BBIO or GRFS?

Do insiders and institutionals have more ownership in BBIO or GRFS?

Do analysts prefer BBIO or GRFS?

Is BBIO or GRFS more profitable?

Which has stronger valuation & earnings, BBIO or GRFS?

Which has more risk & volatility, BBIO or GRFS?

Summary

How does Grifols compare to Halozyme Therapeutics?

Which has preferable valuation and earnings, GRFS or HALO?

Do analysts prefer GRFS or HALO?

Do institutionals & insiders hold more shares of GRFS or HALO?

Does the media favor GRFS or HALO?

Which has more volatility & risk, GRFS or HALO?

Is GRFS or HALO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools